Sarepta Announces CEO Departure But Remains On Track For DMD Drug Approval

CEO of Sarepta resigned on Tuesday but company states it remains on track for Eteplirsen approval, names Kaye interim CEO. Stock up 6%.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.